We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.
Customize Consent Preferences
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Always Active
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
No cookies to display.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
No cookies to display.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
No cookies to display.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
No cookies to display.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
[00:45] Practice-changing results of T-DXd in HER2-low breast cancer
[03:52] Spectacular results for dostarlimab in mismatch repair deficient rectal cancer
[06:27] Ifosfamide is likely to be the go-to-therapy in recurrent Ewing sarcoma
[08:58] Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma
[11:26] New standard-of-care for cisplatin-ineligible LAHNSCC
[13:58] Panitumumab beats bevacizumab in RAS wild-type left-sided metastatic colorectal cancer
Panitumumab beats bevacizumab in RAS wild-type left-sided metastatic colorectal cancer
In this episode (17:16), Medicom’s correspondent covers 6 presentations from the American Society of Clinical Oncology (ASCO 2022) annual meeting, held virtually and in-person from 3-7 June 2022 . The topics discussed are:
Practice-changing results of T-DXd in HER2-low breast cancer Trastuzumab deruxtecan (T-DXd) outperformed therapy by physician’s choice in patients with HER2-low unresectable or metastatic breast cancer who had received 1 or 2 previous lines of chemotherapy. T-DXd is the first HER2-targeted therapy to outperform the standard-of-care in terms of progression-free survival and overall survival in the hard-to-treat HER2-low breast cancer population.
Spectacular results for dostarlimab in mismatch repair deficient rectal cancer A phase 2 trial, investigating neoadjuvant treatment with the PD-1 inhibitor dostarlimab in patients with stage II or III mismatch repair deficient rectal cancer showed a response rate of 100% following treatment with this agent in the thus far analysed patients. Off-protocol use of neoadjuvant immunotherapy in this population is likely to occur.
Ifosfamide is likely to be the go-to-therapy in recurrent Ewing sarcoma Ifosfamide was more efficacious than topotecan plus cyclophosphamide in patients with primary recurrent or refractory Ewing sarcoma, despite a higher discontinuation rate due to toxicity in the ifosfamide arm. The phase 3 rEECur trial is the first randomised study to deliver efficacy, safety, and quality-of-life data to inform physicians on chemotherapy treatment decisions for patients with recurrent Ewing sarcoma.
New standard-of-care for cisplatin-ineligible LAHNSCC Docetaxel added to radiation improved the disease-free survival (DFS) and overall survival (OS) of patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current randomised trial is the first study to assess docetaxel as a radiosensitiser in cisplatin-ineligible patients with LAHNSCC and resulted in the presentation of a new reference standard-of-care for this population.
Panitumumab beats bevacizumab in RAS wild-type left-sided metastatic colorectal cancer Panitumumab was superior to bevacizumab when added to mFOLFOX6 as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC), especially in patients with left-sided tumours. The results of the phase 3 PARADIGM trial support mFOLFOX6 plus panitumumab as first-line therapy in patients with RAS wild-type left-sided mCRC.